Alnylam to Webcast Presentations at Upcoming November Investor Conferences
07 11월 2023 - 10:00PM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that management will present
company overviews at the following conferences:
- Jefferies London Healthcare Conference on Tuesday, November 14,
2023 at 10:00 am GMT (5:00 am ET) in London
- Stifel 2023 Healthcare Conference on Tuesday, November 14, 2023
at 9:45 am ET at the Lotte New York Palace Hotel in New York
City
- Piper Sandler 35th Annual Healthcare Conference on Wednesday,
November 29, 2023 at 9:30 am ET at the Lotte New York Palace Hotel
in New York City
A live audio webcast of each presentation will be available on
the Investors section of the Company’s website at
www.alnylam.com/events. A replay will be available on the Alnylam
website within 48 hours after each event.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation
of RNA interference (RNAi) into a whole new class of innovative
medicines with the potential to transform the lives of people
afflicted with rare and prevalent diseases with unmet need. Based
on Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically validated approach yielding transformative
medicines. Since its founding in 2002, Alnylam has led the RNAi
Revolution and continues to deliver on a bold vision to turn
scientific possibility into reality. Alnylam’s commercial RNAi
therapeutic products are ONPATTRO® (patisiran), AMVUTTRA®
(vutrisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and
Leqvio® (inclisiran), which is being developed and commercialized
by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of
investigational medicines, including multiple product candidates
that are in late-stage development. Alnylam is executing on its
“Alnylam P5x25” strategy to deliver transformative medicines in
both rare and common diseases benefiting patients around the world
through sustainable innovation and exceptional financial
performance, resulting in a leading biotech profile. Alnylam is
headquartered in Cambridge, MA. For more information about our
people, science and pipeline, please visit www.alnylam.com and
engage with us on X (formerly Twitter) at @Alnylam, or on LinkedIn,
Facebook, or Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231107524076/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media) 617-682-4340
Josh Brodsky (Investors) 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024